drugset / Trial / NCT05452928

Aciclovir Versus Placebo for HSV-2 Meningitis

NCT05452928

Phase 4 Not yet recruiting 150 enrolled Jacob Bodilsen
RandomizedParallel-groupQuadruple-blindTreatment

Summary

To determine whether active treatment with (val)acyclovir is superior for treatment of viral meningitis compared with placebo assessed by numbers meeting a primary, objective endpoint at 7 days after randomisation

Timeline

Start
2026-06-01
Primary completion
2028-06-01
Completion
2029-06-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator Acyclovir Small molecule 10 mg/kg
Comparator Valacyclovir Unknown 1 g Oral